Living-Donor Liver Transplant Follow-Up: A Single Center Experience

被引:1
作者
Laeeq, Syed Mudassir [1 ]
Hanif, Farina M. [1 ]
Luck, Nasir Hassan [1 ]
Mandhwani, Rajesh Kumar [1 ]
Iqbal, Jawed [1 ]
Mehdi, Syed Haider [2 ]
机构
[1] Sindh Inst Urol & Transplantat, Dept Hepatogastroenterol, Karachi 74200, Pakistan
[2] Sindh Inst Urol & Transplantat, Dept Hepatobiliary Surg, Karachi, Pakistan
关键词
Anti-viral agents; Diabetes mellitus; Dyslipidemia; HCV; Hypertension; HEPATITIS-C VIRUS; RISK-FACTORS; HCV; SOFOSBUVIR; INFECTION; RIBAVIRIN;
D O I
10.6002/ect.mesot2016.P122
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Liver transplant is a definite treatment of decompensated liver disease. Because of the shortage of livers from deceased donors, living-donor liver transplant is becoming more common. Here, we analyzed our clinical experience in the follow-up care of these patients. Materials and Methods: Liver transplant recipients seen at the Sindh Institute of Urology and Transplantation (Karachi, Pakistan) were included in this analysis. Baseline characteristics and follow-up events were recorded. Results: Our study population included 76 liver transplant patients registered at our clinic. Median age was 42 years, with 62 patients (81.6%) being males. The most common indication of transplant was hepatitis C virus-related cirrhosis (42 patients; 55%), followed by hepatitis B-hepatitis D virus coinfection (8 patients; 10.5%). Anastomotic biliary stricture developed in 16 patients (21.1%), which required biliary stenting. Biliary leak developed in 5 patients (6.6%), and renal cell carcinoma developed in 1 patient. Two recipients died due to hepatitis C virus-related fibrosing cholestasis hepatitis and pulmonary complications. Posttransplant diabetes mellitus developed in 36 (47.1%), hypertension in 17 (38.6%), and dyslipidemia in 19 patients (25%). Of 42 patients with hepatitis C virus infection, 26 were treated with pegylated interferon and ribavirin, of which 65.3% achieved sustained virologic response at 24 weeks. The other 16 patients received sofosbuvir combined with ribavirin for 24 weeks. A sustained virologic response at 12 weeks was achieved in 5 patients, with not yet determined results in the remaining patients. Seven patients were lost to follow-up. Conclusions: Hepatitis C-related cirrhosis was the most common indication for liver transplant, and infection recurrence was observed in our patients. Biliary anastomotic stricture formation was the most prevalent complication after transplant. As liver transplants are becoming more widely available for Pakistani patients at home and abroad, gastroenterologists and trainees in our country should be sensitized, educated, and skilled in the posttransplant care of these patients.
引用
收藏
页码:254 / 257
页数:4
相关论文
共 18 条
[1]   Host and donor risk factors before and after liver transplantation that impact HCV recurrence [J].
Berenguer, M .
LIVER TRANSPLANTATION, 2003, 9 (11) :S44-S47
[2]   Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation [J].
Charlton, Michael ;
Gane, Edward ;
Manns, Michael P. ;
Brown, Robert S., Jr. ;
Curry, Michael P. ;
Kwo, Paul Y. ;
Fontana, Robert J. ;
Gilroy, Richard ;
Teperman, Lewis ;
Muir, Andrew J. ;
McHutchison, John G. ;
Symonds, William T. ;
Brainard, Diana ;
Kirby, Brian ;
Dvory-Sobol, Hadas ;
Denning, Jill ;
Arterburn, Sarah ;
Samuel, Didier ;
Forns, Xavier ;
Terrault, Norah A. .
GASTROENTEROLOGY, 2015, 148 (01) :108-117
[3]   Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study [J].
Curry, Michael P. ;
Forns, Xavier ;
Chung, Raymond T. ;
Terrault, Norah A. ;
Brown, Robert, Jr. ;
Fenkel, Jonathan M. ;
Gordon, Fredric ;
O'Leary, Jacqueline ;
Kuo, Alexander ;
Schiano, Thomas ;
Everson, Gregory ;
Schiff, Eugene ;
Befeler, Alex ;
Gane, Edward ;
Saab, Sammy ;
McHutchison, John G. ;
Subramanian, G. Mani ;
Symonds, William T. ;
Denning, Jill ;
McNair, Lindsay ;
Arterburn, Sarah ;
Svarovskaia, Evguenia ;
Moonka, Dilip ;
Afdhal, Nezam .
GASTROENTEROLOGY, 2015, 148 (01) :100-U519
[4]   Analysis of adult 20-year survivors after liver transplantation [J].
Dopazo, C. ;
Bilbao, I. ;
Castells, L. L. ;
Sapisochin, G. ;
Moreiras, C. ;
Campos-Varela, I. ;
Echeverri, J. ;
Caralt, M. ;
Lazaro, J. L. ;
Charco, R. .
HEPATOLOGY INTERNATIONAL, 2015, 9 (03) :461-470
[5]   EASL Recommendations on Treatment of Hepatitis C 2016 [J].
European Association for the Study of the Liver easloffice@easloffice.eu .
JOURNAL OF HEPATOLOGY, 2017, 66 (01) :153-194
[6]   Indications for liver transplantation in adults [J].
Graziadei, Ivo ;
Zoller, Heinz ;
Fickert, Peter ;
Schneeberger, Stefan ;
Finkenstedt, Armin ;
Peck-Radosavljevic, Markus ;
Mueller, Helmut ;
Kohl, Claudia ;
Sperner-Unterweger, Barbara ;
Eschertzhuber, Stephan ;
Hofer, Harald ;
Oefner, Dietmar ;
Tilg, Herbert ;
Vogel, Wolfgang ;
Trauner, Michael ;
Berlakovich, Gabriela .
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) :679-690
[7]   Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation [J].
Graziadei, Ivo W. ;
Zoller, Heinz M. ;
Schloegl, Anna ;
Nachbaur, Karin ;
Pfeiffer, Karl-Peter ;
Mark, Walter ;
Mikuz, Gregor ;
Pratschke, Johann ;
Margreiter, Raimund ;
Vogel, Wolfgang .
LIVER TRANSPLANTATION, 2012, 18 (06) :671-679
[8]   Posttransplant De Novo Hepatitis C Virus Infection in Renal Transplant Recipients: Its Impact on Morbidity and Mortality [J].
Hanif, Farina M. ;
Laeeq, S. Muddasir ;
Luck, Nasir Hassan ;
Aziz, Tahir ;
Abbas, Zaigham ;
Mubarak, Muhammed .
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2017, 15 (01) :56-60
[9]   Prevalence and risk factors of obesity, hypertension, dyslipidemia and diabetes mellitus before and after adult living donor liver transplantation [J].
Hara, Yasuyuki ;
Kawagishi, Naoki ;
Nakanishi, Wataru ;
Tokodai, Kazuaki ;
Nakanishi, Chikashi ;
Miyagi, Shigehito ;
Ohuchi, Noriaki .
HEPATOLOGY RESEARCH, 2015, 45 (07) :764-770
[10]  
Khademolhosseini F, 2009, MEJDD, V1, P63, DOI [10.15171/midclle, DOI 10.15171/MIDDLE]